GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
Women Lose More Weight on GLP-1 Drugs Than Men Do
This systematic review and meta-analysis examined weight changes among adults with obesity, diabetes, or cardiovascular disease treated with…
• Women lose 11% weight versus 7% for men on these drugs • Helps adults using Wegovy Ozempic and similar weight loss medications • Works sam…
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
Narrative review compares tirzepatide and semaglutide for obesity and type 2 diabetes outcomes
New Obesity Drug Shows Stronger Weight Loss Than Popular Option
This narrative review evaluates tirzepatide versus semaglutide in individuals with obesity or type 2 diabetes mellitus.
This review shows that tirzepatide outperforms semaglutide for weight and blood sugar, but semaglutide currently has stronger proof for prot…
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
A Common Medication Side Effect May Have a Surprising New Solution
This narrative review evaluates the efficacy and safety of glucocorticosteroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID…
Doctors are exploring a new way to protect patients from the dangerous blood sugar spikes caused by essential steroid medications.
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
Observational study links GLP-1 RA to lower risk than SGLT2i in heart failure patients
An observational study using real-world EHR data from Stony Brook University Hospital compared GLP-1 RAs to SGLT2 inhibitors in patients wit…
In heart failure patients, GLP-1 receptor agonists showed a lower risk of death or hospitalization compared to SGLT2 inhibitors over one yea…
Subgroup analysis finds tirzepatide superior to dulaglutide for HbA1c and weight in type 2 diabetes
For people struggling with diabetes on dulaglutide, could switching drugs help?
This subgroup analysis of a phase IV RCT examined adults with type 2 diabetes inadequately controlled on dulaglutide.
Switching from dulaglutide to tirzepatide led to greater drops in blood sugar and body weight for adults with type 2 diabetes after 40 weeks…
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF
New drugs may lower heart failure risk and improve walking distance for patients with preserved ejection fraction
This network meta-analysis evaluated 48,235 patients with heart failure with preserved ejection fraction (HFpEF) treated with various pharma…
New heart drugs lower death risk and hospital visits for patients with preserved ejection fraction while improving walking distance.
GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects
Can diabetes drugs help Wolfram syndrome? A new study looks at real-world use
A retrospective cohort study of 84 participants with genetically confirmed Wolfram syndrome and insulin-dependent diabetes found 35% had rec…
Doctors prescribed diabetes drugs to 35% of rare Wolfram syndrome patients, but records show no improvement in blood sugar, weight, or slowi…